You can reach us via email at [email protected] or by phone at +447549535125 for any inquiries or support
However, the absence of human clinical trials means the relevance and safety of these mechanisms in humans remains unestablished
protect from light Solubility: Sterile water, bacteriostatic water, PBS, or suitable laboratory buffer In vitro working concentration: 25 M used in multiple published studies Distributed by: Peptides Lab UK Quality assurance: Rigorous batch-level analysis
Introduction We focused on the stable gastric pentadecapeptide BPC 157 ( Thus, we suggest that one single application of the NO-synthase (NOS) blocker N(G)-nitro-L-arginine methyl ester (L-NAME) may induce retinal ischemia in rats, and that the stable pentadecapeptide BPC 157 may be the therapy, since it may interact with the NO-system and may counteract various adverse effects of L-NAME application (see In the previous eye research studies, BPC 157 counteracts atropine-mydriasis, but it also opposes an immediate and hour-lasting miotic effect of L-NAME in rats and guinea pigs, and participates in pupil control potentially via NO-mediated and cholinergic mechanisms ( This may be essential for the effective counteraction of the damaging effect of the retrobulbar L-NAME application
Enhances overall recovery after intense workouts, physical trauma, or major surgery
